Xuejun J Liu from 13305 Winstanley Way, San Diego, CA 92130, age 59, Phone: (858)4610204

Principal Engineer, Physical Design

view source

Location:

San Diego, CA

Industry:

Computer Hardware

Work:

Qualcomm Sep 2012 - Oct 2015
Staff Pd Engineer
Broadcom Sep 2012 - Oct 2015
Principal Engineer, Physical Design
Toshiba America Electronic Components, Inc. Nov 1998 - Aug 2012
Staff Design Engineer

Education:

Purdue University 1994 - 1995
Masters, Master of Science In Electrical Engineering, Engineering Wuhan University 1983 - 1987
Bachelors, Bachelor of Science, Electrical Engineering

Skills:

Ic
Signal Integrity
Timing Closure
Soc
Verilog
Digital Signal Processors

Interests:

Children
Environment
Education
Science and Technology
Health

Xuejun Liu

view source

Location:

3100 Sawtelle Blvd, Los Angeles, CA 90066

Industry:

Pharmaceuticals

Work:

Xuejun Liu
Chief Executive Officer

Skills:

Lifesciences
Data Analysis
Biotechnology
Bioinformatics
Translational Medicine
Tao
Immunology
Drug Development
Biomarkers
Statistics
Biomarker Discovery
Drug Discovery

Xuejun Liu

view source

Xuejun Liu

view source

Location:

San Diego, CA

Xuejun Liu

view source

Xuejun Liu

view source

Us Patents

Identification Of Antigenic Peptides From Multiple Myeloma Cells
view source
US Patent:

8075895, Dec 13, 2011
Filed:

Sep 22, 2009
Appl. No.:

12/564501
Inventors:

Zeling Cai - San Diego CA, US
Wei-Xing Shi - San Diego CA, US
Xuejun P. Liu - San Diego CA, US
Jiejun Wu - San Diego CA, US
Assignee:

Janssen Pharmaceutica N.V. - Beerse
International Classification:

A61K 39/00
C07K 14/00
US Classification:

4241841, 530300
Abstract:

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Identification Of Antigenic Peptides From Multiple Myeloma Cells
view source
US Patent:

8232101, Jul 31, 2012
Filed:

Oct 31, 2011
Appl. No.:

13/285459
Inventors:

Zeling Cai - San Diego CA, US
Wei-Xing Shi - San Diego CA, US
Xuejun P. Liu - San Diego CA, US
Jiejun Wu - San Diego CA, US
Assignee:

Janssen Pharmaceutica N.V. - Beerse
International Classification:

C12N 5/00
A61K 38/00
C07K 14/00
US Classification:

435375, 435405, 530327, 530328
Abstract:

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Identification Of Antigenic Peptides From Multiple Myeloma Cells
view source
US Patent:

8323655, Dec 4, 2012
Filed:

Oct 31, 2011
Appl. No.:

13/285517
Inventors:

Zeling Cai - San Diego CA, US
Wei-Xing Shi - San Diego CA, US
Xuejun P. Liu - San Diego CA, US
Jiejun Wu - San Diego CA, US
Assignee:

Janssen Pharmaceutica NV - Beerse
International Classification:

A61K 39/00
C07K 14/00
US Classification:

4241841, 530300
Abstract:

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Identification Of Antigenic Peptides From Multiple Myeloma Cells
view source
US Patent:

8323965, Dec 4, 2012
Filed:

Oct 31, 2011
Appl. No.:

13/285491
Inventors:

Zeling Cai - San Diego CA, US
Wei-Xing Shi - San Diego CA, US
Xuejun P. Liu - San Diego CA, US
Jiejun Wu - San Diego CA, US
Assignee:

Janssen Pharmaceutica NV - Beerse
International Classification:

C12N 5/00
C12N 5/08
US Classification:

435325, 435372
Abstract:

Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

Gene Expression Profiling Of Antidepressant Action In The Brain
view source
US Patent:

20020156038, Oct 24, 2002
Filed:

Oct 4, 2001
Appl. No.:

09/971900
Inventors:

Pascal Bonaventure - San Diego CA, US
Hongqing Quo - San Diego CA, US
Xuejun Liu - San Diego CA, US
Fredrik Kamme - San Diego CA, US
Bernhard Meurers - La Jolla CA, US
Josepha Leysen - Oud-Turnhout, BE
Margot Bakker - Breda, NL
International Classification:

A61K048/00
C12Q001/68
C12M001/34
US Classification:

514/044000, 435/006000, 435/287200
Abstract:

Implementing gene expression to study drug action in the central nervous system is complicated by functional heterogeneity because of the existence of many different neuronal subtypes within the mammalian brain. The integration of laser capture microdissection (LCM) and RNA amplification with cDNA microarray technology allows for large-scale gene expression analysis at cellular level. Using this approach, we have generated gene expression profiles of imipramine, a reference antidepressant, and a new putative antidepressant, novelR1 in several laser-captured brain nuclei (locus coeruleus, dorsal raphe, hypothalamic paraventricular nucleus and hippocampus) of rats subjected to the chronic mild stress model (CMS) of depression.

Methods And Systems Of Biomolecular Sequence Matching
view source
US Patent:

20030036857, Feb 20, 2003
Filed:

Aug 1, 2002
Appl. No.:

10/209660
Inventors:

Xiang Yao - San Diego CA, US
Heng Dai - San Diego CA, US
Albert Leung - San Diego CA, US
Bin Tian - San Diego CA, US
Wei Zhao - San Diego CA, US
Xuejun Liu - San Diego CA, US
Joseph Ciervo - San Diego CA, US
Simon Smith - San Diego CA, US
Jackson Wan - San Diego CA, US
International Classification:

G06F019/00
G01N033/48
G01N033/50
US Classification:

702/020000
Abstract:

The present invention relates to methods and systems for database comparison and database searching and matching, and specifically to database comparison and database searching and matching of databases containing biomolecular sequences as well as databases comprising matched sequences, as well as the use of databases comprising matched biomolecular sequences. In addition, a database comprising matched sequences or a database comprising matched biomolecular sequences may be accessed via a graphical user interface.

Methods And Algorithms For Performing Quality Control During Gene Expression Profiling On Dna Microarray Technology
view source
US Patent:

20040229245, Nov 18, 2004
Filed:

Jan 6, 2004
Appl. No.:

10/753107
Inventors:

Anton Bittner - Escondido CA, US
Andrew Carmen - San Diego CA, US
Albert Leung - San Diego CA, US
Xuejun Liu - San Diego CA, US
Simon Smith - San Diego CA, US
Li Sun - Carlsbad CA, US
Jackson Wan - San Diego CA, US
Huinian Xiao - San Diego CA, US
Xiang Yao - San Diego CA, US
Lynn Yieh - San Diego CA, US
International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50
US Classification:

435/006000, 702/020000
Abstract:

Methods and algorithms for quality control in gene expression profiling on DNA microarray technology are disclosed including methods and algorithms for assessing quality control of the printing of a DNA microarray, the preparation of an RNA sample, the labeling of probes, the hybridization between a DNA microarray and probes, the result of washing procedures, the result of scanning procedures, and for quantifying the gene expression data produced by imaging the hybridized DNA microarray.

Synthesis Of 4-Chlorokynurenines And Intermediates
view source
US Patent:

20210276942, Sep 9, 2021
Filed:

Feb 11, 2019
Appl. No.:

16/967627
Inventors:

- South San Francisco CA, US
Peter LEEMING - Monrovi CA, US
Emerich EISENREICH - Claremont CA, US
Xuejun Karl LIU - Arcadia CA, US
International Classification:

C07C 227/18
C07C 227/32
C07C 227/16
C07C 269/06
C07C 271/22
C07C 229/36
C07C 227/40
Abstract:

The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.